A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation
Switching from BBI to once-daily iGlarLixi improved glycemic control with significant HbA1c reduction and fewer hypoglycemic events.
Authors
- Alice Cheng (ORCID: https://orcid.org/0000-0003-2729-606X)
- Felipe Lauand
- Soraly Servera
- Vivian Fonseca (ORCID: https://orcid.org/0000-0002-3381-7151)
- İnan Anaforoğlu
- Francesco Giorgino (ORCID: https://orcid.org/0000-0001-7372-2678)
- A. Tebaibia
- Zoltán Taybani (ORCID: https://orcid.org/0000-0002-6880-5425)
- Xuan Li (ORCID: https://orcid.org/0000-0003-2202-0080)
Institutions
- Tulane University (US)
- Trillium Health Centre (CA)
- University Medical Center New Orleans (US)
- Sanofi (France) (FR)
- Acıbadem University (TR)
- Türkisch-Deutsche Universität (TR)
- University of Algiers 3 (DZ)
- Sanofi (United States) (US)
- Békés Megyei Központi Kórház (HU)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Diabetes Research and Clinical Practice
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1016/j.diabres.2025.112945
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi